RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $50
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and lowers the price target from $51 to $50.
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and lowers the price target from $51 to $50.